Founded in 2017 in Santa Cruz, California, Claret Bioscience develops innovative next-generation sequencing (NGS) technologies that help researchers recover more information from challenging DNA and RNA samples. Our multidisciplinary team combines expertise in molecular biology, genomics, and assay development to create flexible library preparation and sequencing solutions for applications ranging from cell-free DNA and FFPE to methylation analysis, ancient DNA, oligos, and RNA. Claret’s technologies include SRSLY®, our single-reaction, single-stranded DNA library preparation platform, as well as REALLY and FORSHEAR, which expand the possibilities for working with fragmented, damaged, low-input, and otherwise challenging nucleic acid samples. We are driven by a simple goal: develop better tools for extracting meaningful biological information from every molecule - from start to finish. Follow us for product updates, SERIOUS Talks, webinars, scientific resources, and conferences where you can meet the Claret team.
Looking for a particular Claret Bioscience employee's phone or email?
The Claret Bioscience annual revenue was $6 million in 2026.
Ed Green is the Co-Founder of Claret Bioscience.
8 people are employed at Claret Bioscience.
Claret Bioscience is based in Scotts Valley, California.
The NAICS codes for Claret Bioscience are [541714, 541, 54, 54171, 5417].
The SIC codes for Claret Bioscience are [873, 87].